Access to new medicines in New Zealand compared to Australia

New Zealand Medical Journal

Volumn 124, Issue 1346, 2011, Pages 12-28

  Wonder, Michael ^a   Milne, Richard ^b  

^a Health Outcomes Associates Ltd ^*

^b UNIVERSITY OF AUCKLAND   (New Zealand)

Author keywords

[No Author keywords available]

Indexed keywords

ABATACEPT; AMISULPRIDE; AMPRENAVIR; ANECORTAVE; BIMATOPROST; BISOPROLOL; EPLERENONE; EPTIFIBATIDE; FENOFIBRATE; GLIMEPIRIDE; HIRULOG; INSULIN DETEMIR; LANTHANUM; MELOXICAM; PARATHYROID HORMONE[1-34]; PIOGLITAZONE; PRASUGREL; PRESCRIPTION DRUG; RANIBIZUMAB; RECOMBINANT INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; ROSIGLITAZONE; ROSUVASTATIN; SEVELAMER; STRONTIUM; TENOFOVIR; TIOTROPIUM BROMIDE; TIPRANAVIR; TRAVOPROST; UNINDEXED DRUG; VERTEPORFIN; DRUG;

ACROMEGALY; ACUTE CORONARY SYNDROME; ACUTE HEART INFARCTION; ALZHEIMER DISEASE; ARTICLE; ASPERGILLOSIS; ASTHMA; ATOPIC DERMATITIS; AUSTRALIA; BONE METASTASIS; BREAST CANCER; CHRONIC KIDNEY DISEASE; COLORECTAL CANCER; CONTROLLED STUDY; DEPRESSION; DYSLIPIDEMIA; EPILEPSY; HEALTH CARE ACCESS; HEART FAILURE; HEPATITIS B; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPERPHOSPHATEMIA; HYPERTENSION; KIDNEY TRANSPLANTATION; LARYNX CANCER; LIVER CELL CARCINOMA; LUNG NON SMALL CELL CANCER; MOTOR NEURON DISEASE; MULTIPLE MYELOMA; MULTIPLE SCLEROSIS; MYELOID LEUKEMIA; NARCOLEPSY; NAUSEA AND VOMITING; NEW ZEALAND; NON INSULIN DEPENDENT DIABETES MELLITUS; OSTEOARTHRITIS; OSTEOPOROSIS; PAIN; PARKINSON DISEASE; PROSTATE CANCER; PSORIASIS VULGARIS; PULMONARY HYPERTENSION; RADIOTHERAPY; REIMBURSEMENT; RETINA MACULA AGE RELATED DEGENERATION; RHEUMATOID ARTHRITIS; SEPSIS; SQUAMOUS CELL CARCINOMA; COMPARATIVE STUDY; DRUG APPROVAL; DRUG LEGISLATION; ECONOMICS; EDITORIAL; FEMALE; HEALTH CARE DELIVERY; HEALTH INSURANCE; MALE; PRESCRIPTION; STATISTICS;

AUSTRALIA; DRUG APPROVAL; DRUG PRESCRIPTIONS; FEMALE; HEALTH SERVICES ACCESSIBILITY; HUMANS; INSURANCE, PHARMACEUTICAL SERVICES; LEGISLATION, DRUG; MALE; NEW ZEALAND; PHARMACEUTICAL PREPARATIONS;

EID: 84855860908     PISSN: None     EISSN: 11758716     Source Type: Journal    
DOI: None     Document Type: Article

References (48)

1. PHARMAC. Introduction to PHARMAC. http://www.pharmac.govt.nz/2008/12/16/01_PHARM_Infsheet_INTRO.pdf
2. Australian Government. Department of Health and Ageing. About the PBS. http://www.pbs.gov.au/info/about-the-pbs
3. PHARMAC. New Zealand Pharmaceutical Schedule. http://www.pharmac.govt.nz/schedule.asp
4. Australian Government. Department of Health and Ageing. Schedule of Pharmaceutical Benefits. http://www.pbs.gov.au/html/home
5. Australian Government. Department of Health and Ageing. Therapeutic Goods Administration. eBS Australian Register of Therapeutic Goods Medicines. https://www.ebs.tga.gov.au/ebs/ANZTPAR/PublicWeb.nsf/cuMedicines?OpenView
6. New Zealand Medicines and Medical Devices Safety Authority (Medsafe). www.medsafe.govt.nz/reg.htm
7. World Health Organization. WHO Collaborating Centre for Drug Statistics Methodology. www.whocc.no/atcddd/
8. GraphPad. GraphPad Software Inc. http://www.graphpad.com/quickcalcs/index.cfm
9. Australian Government. Department of Health and Ageing. PBS Publications. PBAC Outcomes and Public Summary Documents. Public Summary Documents. Public Summary Documents by Product. Ropinirole, tablets, 0.25 mg, 0.5 mg and 2 mg, Repreve March 2006. http://www.health.gov.au/internet/main/publishing.nsf/Content/pbac-psd-ropinirole-mar06
10. Australian Government. Department of Health and Ageing. PBS Publications. PBAC Outcomes and Public Summary Documents. PBAC Outcomes by Meeting. June 2003 PBAC Outcomes - Subsequent Decisions not to Recommend. http://www.health.gov.au/internet/main/publishing.nsf/Content/health-pbs-general-listing-pbacrec-jun03-reject2.htm
11. Australian Government. Department of Health and Ageing. Department of Health and Ageing. Drugs designated as orphan drugs. http://www.tga.gov.au/docs/html/orphand2.htm
12. Harris AH, Hill SR, Chin G, Li JJ, Walkom E. The role of value for money in public insurance coverage decisions for drugs in Australia: a retrospective analysis 1994-2004. Med Decis Making 2008;28(5):713-22.
13. Australian Government. Pharmaceutical Benefits Pricing Authority Annual Report for the year ended 30 June 2010. http://www.health.gov.au/internet/main/publishing.nsf/Content/74C7CDABFFEFC8A0CA256F180046E152/$File/PBPA%20Annual%20Report%20final.pdf
14. Australian Government. Department of Health and Ageing. PBS Publications. Guidelines for preparing submissions to the PBAC - December 2008. http://www.health.gov.au/internet/main/publishing.nsf/content/pbacguidelines-index
15. Grocott R. Applying programme budgeting marginal analysis in the health sector: 12 years of experience. Expert Rev 2009;9(2):181-7.
16. PHARMAC. Prescription for pharmacoeconomic analysis, version 2. Wellington: PHARMAC; 2007.
17. Australian Government. Department of Health and Ageing. PBS Publications. Public Summary Documents by Product. http://www.health.gov.au/internet/main/publishing.nsf/Content/public-summary-documents-by-product
18. Metcalfe S, Burgess C, Laking G, Evans J, Wells S, Crausaz S. Trastuzumab: possible publication bias. Lancet. 2008;371(9625):1646-8.
19. Metcalfe S, Evans J. PHARMAC responds on Herceptin assumptions and decisions. N Z Med J. 2007;120 (1260):U2692.
20. Metcalfe S, Evans J, Priest G. PHARMAC funding of 9-week concurrent trastuzumab (Herceptin) for HER2-positive early breast cancer. N Z Med J. 2007;120(1256):U2593.
21. Moodie P. More from PHARMAC on long-acting insulin analogues: insulin glargine now funded. N Z Med J. 2006;119(1236):U2040.
22. Metcalfe S, Evans J, Moodie P. PHARMAC responds on long-acting insulin analogues. N Z Med J. 2005;118 (1224):U1716.
23. Metcalfe S, Moodie P. More on PHARMAC and tobacco control in New Zealand. N Z Med J. 2006;119 (1228):U1837.
24. Metcalfe S, Moodie P, McNee W. PHARMAC and tobacco control in New Zealand: two licensed funded options are already available. N Z Med J. 2005;118 (1217):U1544; author reply U1544; discussion U1544.
25. Metcalfe S, Crausaz S, Moodie P, McNee W. PHARMAC's response on temozolomide and funding costly medicines that prolong life shortly. N Z Med J 2005;118 (1227):U1806.
26. Metcalfe S, Rasiah D, Dougherty S. PHARMAC responds on treatments for pulmonary arterial hypertension. N Z Med J. 2005;118 (1227):U1805.
27. Metcalfe S, Moodie P, Grocott R, Wilkinson T. PHARMAC responds on TNF inhibitors for inflammatory arthritis. N Z Med J. 2005;118 (1227):U1799.
28. Metcalfe S, Dougherty S. PHARMAC responds on long-acting inhalers for COPD. N Z Med J. 2005;118 (1225):U1743.
29. Grocott R, Metcalfe S. Going against the flow: the impact of PHARMAC not funding COX-2 inhibitors for chronic arthritis. NZ Med J 2005;118 (1223):U1690.
30. Moodie P. PHARMAC and cardiovascular health in New Zealand. N Z Med J. 2008;121 (1270):102-5.
31. Metcalfe S, Moodie P. PHARMAC and statins--correction is needed. N Z Med J. 2007;120(1250):U2453.
32. Moodie P, Dougherty S, Metcalfe S. PHARMAC and statins--getting the best population health gains. N Z Med J. 2006;119 (1238):U2092.
33. Moodie P, Metcalfe S, McNee W. Response from PHARMAC: difficult choices. N Z Med J. 2003;116 (1170):U361.
34. Metcalfe S, Moodie P. More about cardiovascular disease and lipid management in New Zealand. N Z Med J. 2002;115 (1163):U203.
35. Metcalfe S, Wilkinson T, Rasiah D. PHARMAC responds on agents to prevent osteoporotic fractures. N Z Med J. 2006;119 (1230):U1895.
36. Davies A, Metcalfe S, Moodie P, McNee W. PHARMAC responds to Stewart Mann on dihydropyridine calcium channel antagonists. N Z Med J. 2005;118 (1220):U1621.
37. Pharmaceutical Management Agency Annual Report for the year ended 30 June 2010. http://www.pharmac.govt.nz/2010/10/22/2010%20Annual%20Report.pdf
38. Lichtenberg FR. Have newer cardiovascular drugs reduced hospitalization? Evidence from longitudinal country-level data on 20 OECD countries, 1995-2003. Health Econ 2009;18 (5):519-34.
39. Australian Government. Department of Health and Ageing. PBS Publications. PBS Expenditure and Prescriptions. http://www.health.gov.au/internet/main/publishing.nsf/Content/pbs_expenditure_prescriptions-copy1
40. PHARMAC. Annual Review. Wellington: Pharmaceutical Management Agency PHARMAC; 2010. http://www.pharmac.govt.nz/2010/12/15/2010AnnRev.pdf
41. Danzon PM, Wang YR, Wang L. The impact of price regulation on the launch delay of new drugs - evidence from twenty-five major markets in the 1990s. Health Economics 2005;14 (3):269-92.
42. Castalia Strategic Advisors. New Zealand Pharmaceutical Policies. August 2005. http://www.castalia.fr/SITE_Default/x-files/14634.pdf
43. Easton B. New Zealand's Pharmaceutical Policies: A Fresh Look. November 2005. www.pharmac.govt.nz/pdf/040506a.pdf
44. Business and Economic Research Limited. Independent Review of the Castalia Report on New Zealand Pharmaceutical Policies. October 2005. http://www.pharmac.govt.nz/pdf/040506b.pdf
45. Morgan SG, McMahon M, Mitton C, Roughead E, Kirk R, Kanavos P, Menon P. Centralized drug review processes in Australia, Canada, New Zealand, and the United Kingdom. Health Affairs 2006;25 (2):337-47.
46. Morgan SG, McMahon M, Mitton C, Roughead E, Kirk R, Kanavos P, Menon P. Drugs down under [letter - author reply]. Health Affairs 2006;25 (4):1185-6.
47. Karolinska Institute. Market uptake of new oncology drugs. Ann Oncol 2007;18 9 Suppl 3:iii31-iii48.
48. PHARMAC. PHARMAC releases data on Australia vs. NZ comparison. Media release 20 March 2006. www.pharmac.govt.nz/pdf/200306.pdf